TNF and inflammatory bowel disease: In subgroup analysis by IBD phenotype, vedolizumab was associated with a 77% higher risk of experiencing treatment failure vs TNF antagonists among patients with CD (adjusted HR, 1.77; 95% CI, 1.21-2.58), whereas no significant differences in the risk of treatment failure were observed among patients with UC (adjusted HR, 1.04; 95% CI, 0.75-1.43; P = .03 for interaction) (Figure 2; Table 2).